Biotechnology

T-cells treated by Turn Biotechnologies show increased cancer-killing effectiveness

* Preclinical data showing how ERA™, eTurna™ technologies turbocharge T-cell therapies presented at New Frontiers of RNA Nanotherapeutics meeting today * ERA™ boosts CAR T-cell efficacy by overcoming T-cell exhaustion that inhibits cancer cures * eTurna™ delivery platform delivers more healt...

2022-10-24 23:30 3628

deCODE genetics publishes multiomics study of nonalcoholic fatty liver disease

Scientists at deCODE genetics in Iceland have discovered rare, protective loss-of-function variants that point to potential drug targets for nonalcoholic fatty liver disease (NAFLD). REYKJAVIK, Iceland, Oct. 24, 2022 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, publish t...

2022-10-24 23:00 3714

Transcenta to Participate in Four Upcoming Conferences

SUZHOU, China, Oct. 24, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical-stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development, and manufacturing of antibody-based therapeutics, announces that the management ...

2022-10-24 21:00 4395

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults

GAITHERSBURG, Md., Oct. 22, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received eme...

2022-10-22 03:25 8990

Antengene Announces XPOVIO® Regulatory Approval in Taiwan for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma

-       XPOVIO® is the first and only exportin 1 (XPO1) inhibitor approved in Taiwan -       Antengene plans to submit for national health insurance reimbursement inTaiwan for XPOVIO® in Q4 2022 SHANGHAI and HONG KONG, Oct. 21, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2022-10-21 20:37 6047

SIRONA completes enrollment - A leap in the DCB treatment of femoropopliteal arterial disease

TAMPA, Fla., Oct. 21, 2022 /PRNewswire/ -- Concept Medical Inc.  announces the successful completion of the SIRONA - World's first and the largest head-to-head RCT investigating the use of Sirolimus Drug Coated Balloon (DCB) (Magic Touch PTA

2022-10-21 20:36 4424

MGI Contributes to Thailand's Roadmap for Genomic Medicine in Genomics Thailand Initiative

BANGKOK, Oct, 21 2022 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, today announced the supply of its products* to support the sequencing of the genomes of 50,000 Thai individuals as part of the Genomics Thailand Initiativ...

2022-10-21 11:00 4155

AUM Biosciences and Asymchem Complete Phase II API Production Campaign of Novel TRK Inhibitor

TEDA TIANJIN, P.R. China and SINGAPORE, Oct. 20, 2022 /PRNewswire/ -- Asymchem (stock code: 002821.SZ), a leading global contract development and manufacturing service provider, and AUM Biosciences (AUM), a global clinical stage biotech company, focused on discovering, acquiring and developing ne...

2022-10-20 20:30 2840

BGI Australia Receives NATA Certification for Clinical Whole Exome Sequencing

BRISBANE, Australia, Oct. 20, 2022 /PRNewswire/ -- BGI Australia's lab has achieved accreditation from the National Association of Testing Authorities (NATA) to perform clinical Whole Exome Sequencing inAustralia, paving the way for the global life sciences company to provide clinical sequencing ...

2022-10-20 15:31 2275

Consumer Healthcare Products (CHP) Australia Streamlines Content Management for Life Sciences Companies with Veeva Vault PromoMats

CHP's AdCheck independent advertising advisory service creates content management and communication efficiencies for members SYDNEY, Oct. 20, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced thatAdCheck , an indepen...

2022-10-20 07:05 5532

NCCN Guidelines for Patients Win Award for Excellence in Cancer Patient Education from CPEN

National Comprehensive Cancer Network's breast cancer patient resources honored for unique support of diversity, equity, and inclusion, available free at NCCN.org/patientresources. PLYMOUTH MEETING, Pa., Oct. 19, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance ...

2022-10-19 20:37 1785

Everest Medicines Announces Partner Providence Reports Positive Top-Line Data from Phase 2 Primary Immunization Trial for mRNA COVID-19 Vaccine Candidate in Adults

-- Levels of neutralizing antibodies generated by PTX-COVID19-B were non-inferior to Comirnaty®-- -- PTX-COVID19-B was well tolerated with no safety signals-- -- Everest is filing IND applications for phase 3 clinical trials for booster indication-- SHANGHAI, Oct. 19, 2022 /PRNewswire/ -- Everest...

2022-10-19 20:15 3880

Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022

* Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-tolerated * Results indicate potential for oral once-weekly, long-acting combination therapy for HIV infection, supporting continued clinical development * Additional data presented by Brii's licensing part...

2022-10-19 20:00 3462

EDAN Forays into Molecular Point-of-Care Market with Its First-Ever Molecular Diagnostics Solution Released at Medlab Asia 2022

Developed based on Loop-Mediated Isothermal Amplification (LAMP), the new molecular diagnostics analysis system, ClariLight CL30, gives on-the-spot results and empowers physicians for early infectious disease diagnostics because of its agility, fast and flexibility. BANGKOK, Thailand, Oct. 19, 2...

2022-10-19 19:59 3099

Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences

Sirnaomics Chief Technology Officer Dmitry Samarsky is a featured speaker at the RNA LeadersUSA Congress and 18th Drug Discovery Innovation Programme Gaithersburg, Md. and Suzhou, China, Oct. 19, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK) a leading ...

2022-10-19 14:55 2945

MedAlliance to be Acquired by Cordis

GENEVA, Oct. 19, 2022 /PRNewswire/ -- Swiss-based medical technology company MedAlliance has announced it has entered into an agreement with Cordis for an acquisition which includes an initial investment of$35M and upfront closing payment of$200M, regulatory achievement milestones of up to $125M ...

2022-10-19 08:00 3058

Alphyn Biologics Announces Enrollment Passes Halfway Point in Phase2a Clinical Trial of Mild-to-Moderate Atopic Dermatitis Treatment

Study evaluates AB-101a for patients with and without concurrent bacterial infection ANNAPOLIS, Md., Oct. 18, 2022 /PRNewswire/ -- Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that enrollment in its Phase2a clinical t...

2022-10-18 19:30 2200

NEC Selected as Technology Partner in the Implementation of Biometric Solutions for NIISe

KUALA LUMPUR, Malaysia, Oct. 18, 2022 /PRNewswire/ -- Leading IT and Network Technologies company, NEC Corporation of Malaysia Sdn Bhd (NEC Malaysia) has been awarded the sub-contract for the implementation of its class leading Automated Biometric Identification System (NEC ABIS) and Border Contr...

2022-10-18 17:01 2951

GenScript ProBio Signs MOU to Form Strategic Partnership with GeneCraft To Development and Production of New AAV gene therapies

SEOUL, South Korea, Oct. 18, 2022 /PRNewswire/ -- On the Oct 17, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and GeneCraft  (Suk Chul Bae, CEO), a global research team led by Professor Suk Chul Bae of lung cancer mechanism research, announced that they had entered into a strat...

2022-10-18 08:00 3231

TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM

* OPALESCENCE Phase II feasibility study of TLX250-CDx in patients with triple-negative breast cancer – early results suggest potential to detect carbonic anhydrase IX (CAIX) expression, theranostic potential in this difficult to treat disease. * PERTINENCE Early Phase I feasibility study of ...

2022-10-18 06:43 2228
1 ... 125126127128129130131 ... 185